Figure 3
Correlation of CMAP decrement and clinical state: Data are presented on a group level (boxplot) and for each individual patient (green dots). (A) No clear correlation between clinical severity at testing and CMAP decrement exists, mainly because clinically asymptomatic patients still exhibit pathologic decrements at RNS (B) Correlation of CMAP decrement with the worst recorded MGFA is evident on the group level, but patients with the high CMAP decrement did not necessarily develop severe disease or myasthenic crisis during the observed period. (C) There is no association of CMAP decrement with the outcome of patients at last follow-up.
